Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting.

CONCLUSIONS: Vildagliptin is well tolerated either as monotherapy or in combination but the majority of patients require add-on therapy shortly after the beginning of treatment. PMID: 26355765 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/26355765?dopt=Abstract

Source: Diabetes Metab - September 14, 2015 Category: Endocrinology Authors: Yavropoulou MP, Pikilidou M, Kotsa K, Michopoulos A, Papakonstantinou E, Yovos JG Tags: J Diabetes Metab Disord Source Type: research